Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury

Kidney International

Volumn 82, Issue 6, 2012, Pages 643-651

  Luther, James M ^a   Luo, Pengcheng ^a   Wang, Zuofei ^a   Cohen, Samuel E ^b   Kim, Hyung Suk ^c   Fogo, Agnes B ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

aldosterone; angiotensin; cardiovascular; hypertension; renal injury

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ENDOTHELIN 1; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; NEPHRIN; NITROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; UREA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GENE EXPRESSION; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; HYPOALDOSTERONISM; KIDNEY DISEASE; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; VASCULAR DISEASE;

EID: 84865790123     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.170     Document Type: Article

References (45)

1. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
2. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
3. Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
4. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
5. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
6. Nagata K, Obata K, Xu J et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664.
7. Nagase M, Shibata S, Yoshida S et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093.
8. Du J, Fan YY, Hitomi H et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol 2009; 297: F802-F808.
9. Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111: 3087-3094.
10. Lea WB, Kwak ES, Luther JM et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944.
11. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-650.
12. Mazak I, Fiebeler A, Muller DN et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004; 109: 2792-2800.
13. Luther JM, Wang Z, Ma J et al. Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 2009; 150: 2229-2236.
14. Makhanova N, Lee G, Takahashi N et al. Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 2006; 290: F61-F69.
15. Fiebeler A, Schmidt F, Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37: 787-793.
16. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
17. Rocha R, Martin-Berger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
18. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575.
19. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004; 145: 3153-3157.
20. Neves MF, Amiri F, Virdis A et al. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005; 83: 999-1006.
21. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 2006; 47: 634-635.
22. Wang H, Shimosawa T, Matsui H et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens 2008; 26: 1453-1462.
23. Mulder P, Mellin V, Favre J et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008; 29: 2171-2179.
24. Matsui Y, Jia N, Okamoto H et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1195-1201.
25. Rocha R, Stier Jr CT, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
26. Gomez-Sanchez EP, Gomez-Sanchez CM, Plonczynski M et al. Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension. Exp Physiol 2010; 95: 120-130.
27. Shibata S, Nagase M, Yoshida S et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
28. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55: 813-818.
29. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009; 308: 53-62.
30. Rafiq K, Nakano D, Ihara G et al. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens 2011; 29: 290-298.
31. Brem AS, Morris DJ, Ge Y et al. Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11b-HSD activity. Am J Physiol Renal Physiol 2010; 298: F1178-F1187.
32. Lee SH, Yoo TH, Nam BY et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297: F1381-F1390.
33. Terada Y, Kobayashi T, Kuwana H et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16: 2296-2305.
34. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011; 76: 834-839.
35. Remuzzi G, Perico N, Macia M et al. The role of renin- angiotensinaldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005: S57-S65.
36. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
37. Hollenberg NK. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension 2000; 35: 150-154.
38. Lee G, Makhanova N, Caron K et al. Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 2005; 146: 2650-2656.
39. Weisberg AD, Albornoz F, Griffin JP et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25: 365-371.
40. Quaschning T, Ruschitzka F, Shaw S et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001; 37: 801-805.
41. Ma J, Weisberg A, Griffin JP et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006; 69: 1064-1072.
42. Dunn SR, Qi Z, Bottinger EP et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004; 65: 1959-1967.
43. Collins TJ. ImageJ for microscopy. Biotechniques 2007; 43: 25-30.
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 2001; 25: 402-408.
45. R Development Core Team. A Language and Environment for Statistical Computing 2010##R Foundation for Statistical Computing: Vienna, Austria.